- 1、本文档共32页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
EUROPEAN COMMISSION
DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
Health systems and products
Medical products – quality, safety and innovation
SAFETY FEATURES FOR MEDICINAL PRODUCTS FOR HUMAN USE
QUESTIONS AND ANSWERS - VERSION 17
1
(Submitted for discussion to the Member State expert group on the safety features )
Document history:
Date of submission of draft to the Member State
February 2020
expert group on the safety features :
Date of publication: 9 March 2020
Supersedes: Version 16
Changes compared to superseded version : New QAs: 5.11
Revised QAs: 1.22
Important disclaimer: The views expressed in this questions and answers document are
not a formal interpretation of Union law, nor are legally binding. Ultimately, only the
European Court of Justice can give an authoritative interpretation of Union law. This
document aims at informing on the technical aspects of Commission Delegated
Regulation (EU) 2016/161 with a view to facilitating its implementation.
This documents sets out frequently-asked questions and answers regarding the
implementation of the rules on the safety features for medicinal products for human use.
These rules are enshrined in Articles 47a, 54(o) and 54a of Directive 2001/83/EC, and in
2
Commission Delegated Regulation (EU) 2016/ 161 .
This document is only available in English.
1 http://
您可能关注的文档
- 《过滤器完整性测试仪》标准.pdf
- 《汽化过氧化氢浓度检测仪》标准,VHP检测的精度要求.pdf
- 《中国药典》2020版生物制品异常毒性检查相关修订内容的公示(第二次)20200325.pdf
- APIC:起始物料(RSM)供应商第三方审计问答(中英文对照版).pdf
- CEP证书修订更新指南-2018【中英含译注】.pdf
- EDQM OMCL 试机管理—2019(中英文对照版).pdf
- EDQM 红外光谱仪的确认—2019(中英文对照).pdf
- EDQM 色谱柱的确认_2019(中英文对照版).pdf
- EMA “供上市许可持有人使用的亚硝胺信息”问答20200327.pdf
- EMA 关于使用OOS批次细胞 组织先进治疗药品的问答-2019.pdf
- EMA《临床试验用计算机化系统验证和确认》.pdf
- EU GMP 附录21药物进口-20200320征求意见稿.pdf
- FDA 483报告:印度Cipla(西普拉).pdf
- FDA培训:药品中色素添加剂的法规要求.pdf
- FDA培训课件:ICH Q12上市后变更管理方案.pdf
- FDA 行业指南:气候带III IV中新兽用药物成分和药物产品的稳定性测试.pdf
- FDA 磷酸氯喹产品特定指南:通用药物开发的产品特定指南.pdf
- FDA 硫酸羟氯喹的产品特定指南:通用药物开发的产品特定指南.pdf
- FDA工业指南:Ⅱ型糖尿病:评估改善血糖控制的新药的安全性-2020草案.pdf
- FDA工业指南:仿制药竞争法.pdf
文档评论(0)